Search

Your search keyword '"Tajima, Soichiro"' showing total 16 results
Start Over Author "Tajima, Soichiro" Publication Year Range Last 10 years
16 results on '"Tajima, Soichiro"'

4. Development and Validation of A Liquid Chromatography–Tandem Mass Spectrometry Method to Simultaneously Measure Tacrolimus and Everolimus Concentrations in Kidney Allograft Biopsies After Kidney Transplantation

Author

Zhang, Mengyu, primary, Tajima, Soichiro, additional, Shigematsu, Tomohiro, additional, Noguchi, Hiroshi, additional, Kaku, Keizo, additional, Tsuchimoto, Akihiro, additional, Okabe, Yasuhiro, additional, Egashira, Nobuaki, additional, and Ieiri, Ichiro, additional

Published
2022
Full Text
View/download PDF

5. Development and Validation of an LC-MS/MS Method to Quantify Gilteritinib and Its Clinical Application in Patients with FLT3 Mutation-Positive Acute Myelogenous Leukemia

Author

Zhang, Mengyu, primary, Tajima, Soichiro, additional, Suetsugu, Kimitaka, additional, Hirota, Takeshi, additional, Tsuchiya, Yuichi, additional, Yamauchi, Takuji, additional, Yoshimoto, Goichi, additional, Miyamoto, Toshihiro, additional, Egashira, Nobuaki, additional, Akashi, Koichi, additional, and Ieiri, Ichiro, additional

Published
2022
Full Text
View/download PDF

6. Association Between Immune-Related Hypothyroidism and Survival Outcomes in Patients with Head and Neck Cancer Treated with Nivolumab

Author

Hata, Kojiro, primary, Sasaki, Keiichi, additional, Watanabe, Hiroyuki, additional, Ikeda, Munehiko, additional, Tsuji, Toshikazu, additional, Ishida, Shigeru, additional, Ikebe, Mio, additional, Kumagai, Ayako, additional, Ozawa, Nana, additional, Matsukane, Ryosuke, additional, Nagata, Kenichiro, additional, Suetsugu, Kimitaka, additional, Tajima, Soichiro, additional, Yamada, Takaaki, additional, Egashira, Nobuaki, additional, Matsuo, Mioko, additional, Yasumatsu, Ryuji, additional, Nakagawa, Takashi, additional, and Ieiri, Ichiro, additional

Published
2021
Full Text
View/download PDF

10. Neutrophil Gelatinase-Associated Lipocalin Is Not Associated with Tacrolimus-Induced Acute Kidney Injury in Liver Transplant Patients Who Received Mycophenolate Mofetil with Delayed Introduction of Tacrolimus

Author

Fukuda, Mio, primary, Suetsugu, Kimitaka, additional, Tajima, Soichiro, additional, Katsube, Yurie, additional, Watanabe, Hiroyuki, additional, Harada, Noboru, additional, Yoshizumi, Tomoharu, additional, Egashira, Nobuaki, additional, Mori, Masaki, additional, and Masuda, Satohiro, additional

Published
2019
Full Text
View/download PDF

14. Biomarkers for individualized dosage adjustments in immunosuppressive therapy using calcineurin inhibitors after organ transplantation

Author

Fu, Rao, Tajima, Soichiro, Suetsugu, Kimitaka, Watanabe, Hiroyuki, Egashira, Nobuaki, and Masuda, Satohiro

Abstract

Calcineurin inhibitors (CNIs), such as cyclosporine A and tacrolimus, are widely used immunosuppressive agents for the prevention of post-transplantation rejection and have improved 1-year graft survival rates by up to 90%. However, CNIs can induce severe reactions, such as acute or chronic allograft nephropathy, hypertension, and neurotoxicity. Because CNIs have varied bioavailabilities, narrow therapeutic ranges, and individual propensities for toxic effects, therapeutic drug monitoring is necessary for all CNIs. Identifying the genetic polymorphisms in drug-metabolizing enzymes will help to determine personalized dosage regimens for CNIs, as CNIs are substrates for CYP3A5 and P-glycoprotein (P-gp, MDR1). CNIs are often concomitantly administered with voriconazole or proton pump inhibitors (PPIs), giving rise to drug interaction problems. Voriconazole and PPIs can increase the blood concentrations of CNIs, and both are primarily metabolized by CYP2C19. Thus, it is expected that interactions between CNIs and voriconazole or PPI would be affected by CYP2C19 and CYP3A5 polymorphisms. CNI-induced acute kidney injury (AKI) is a serious complication of transplantations. Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM-1) are noninvasive urinary biomarkers that are believed to be highly sensitive to CNI-induced AKI. In this article, we review the adverse events and pharmacokinetics of CNIs and the biomarkers related to CNIs, including CYP3A5, CYP2C19, MDR1, NGAL, and KIM-1. We hope that these data will help to identify the optimal biomarkers for monitoring CNI-based immunosuppressive therapy after organ transplantation.

Published
2019
Full Text
View/download PDF

15. Characteristics of and Risk Factors for Interstitial Lung Disease Induced by Chemotherapy for Lung Cancer

Author

Sakurada, Takumi, primary, Kakiuchi, Soji, additional, Tajima, Soichiro, additional, Horinouchi, Yuya, additional, Okada, Naoto, additional, Nishisako, Hirotaka, additional, Nakamura, Toshimi, additional, Teraoka, Kazuhiko, additional, Kawazoe, Kazuyoshi, additional, Yanagawa, Hiroaki, additional, Nishioka, Yasuhiko, additional, Minakuchi, Kazuo, additional, and Ishizawa, Keisuke, additional

Published
2015
Full Text
View/download PDF

16. Pemetrexed-Induced Rash May Be Prevented by Supplementary Corticosteroids

Author

Sakurada, Takumi, primary, Kakiuchi, Soji, additional, Tajima, Soichiro, additional, Horinouchi, Yuya, additional, Konaka, Ken, additional, Okada, Naoto, additional, Nishisako, Hirotaka, additional, Nakamura, Toshimi, additional, Teraoka, Kazuhiko, additional, Kawazoe, Kazuyoshi, additional, Yanagawa, Hiroaki, additional, Nishioka, Yasuhiko, additional, and Ishizawa, Keisuke, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results